Viralytics Oncolytic Virotherapy technology is protected by a large suite of patents worldwide - including patents granted in Europe and USA. These provide Viralytics with the exclusive and legally enforceable right to market and manufacture its anticancer virotherapy globally.
More than a dozen patents covering the novel anti-cancer use of numerous Coxsackie Group A viruses and Echoviruses have been granted globally and a further 30 patent applications are pending grant. Five core areas are covered, within each of these areas claims are directed to provide protection over use of the listed oncolytic viruses (within the Coxsackie and Echovirus families), pharmaceutical compositions, production methods, and in some cases composition of matter.
Viralytics is actively undergoing cutting edge research and development to build on and protect its Intellectual Property base. The Company continually monitors new patent and patent applications worldwide.
The pipeline of international granted patents and patent applications stem from the international patent applications listed below. These patents are all assigned to Viralytics Ltd.
| PCT | Invention Name | Inventor(s) | Filing Date | Countries |
|---|---|---|---|---|
|
A Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in the Same.
A method of killing abnormal cells, using a virus recognizing at least one cell adhesion molecule and a complement regulatory protein. Includes Coxsackie A group viruses to treat numerous cancers including melanoma, prostate and breast cancers. |
Darren Shafren |
27-Nov-00 |
Granted: Australia, Europe, USA, New Zealand |
|
|
Pending: Canada, Japan |
||||
|
Divisional Granted: Australia |
||||
|
Divisional Pending: Australia, Europe, USA, Japan |
||||
|
A Method of Treating a Malignancy in a Subject via Direct Picornaviral-Mediated Oncolysis.
Methods for treating abnormal cells in a mammal through direct picornaviral mediated oncolysis, using echoviruses and in combination with Coxsackie A Group viruses – including Coxsackievirus A13, A15 A18 and A21. |
Darren Shafren |
18-Dec-02 |
Granted: Australia, India, New Zealand, Singapore, South Africa, USA, China |
|
|
Pending: Canada, Europe, South Korea, Hong Kong |
||||
|
Divisional Pending: USA, China, Japan, Hong Kong |
||||
|
Modified Oncolytic Viruses.
Method of isolating selected Picornaviruses capable of lytically infecting or inducing apoptosis in a cell in the absence of the intercelluar adhesion molecule-1 receptor. Preferably the selected virus lytically infects a cell through Decay-Accelerating-Factor on the cell surface.
|
Darren Shafren |
11-Mar-04 |
Granted: Australia, South Africa. USA |
|
|
Pending: India |
||||
|
Divisional Pending: New Zealand, USA |
||||
|
Methods and Compositions for Treatment of Hematologic Cancers.
Method of treating or preventing hematologic cancers though administering a therapeutically effective amount of a Picornavirus. This scope of patent application includes naturally occurring Picornaviruses and genetically modified forms of such viruses. |
Gough Au and Darren Shafren |
20-Aug-04 |
Granted: Singapore, South Africa, Australia, China |
|
|
Pending: Canada, Europe, Hong Kong, India, Japan, South Korea, USA |
||||
|
Divisional Pending: New Zealand, Japan
|
||||
|
Method and Composition for Treatment of Neoplasms.
Covers methods of treating a neoplasm in an animal through the use of isolated nucleic acid including synthetic RNA and complementary DNA derived from one or more Picornavirus(es). |
Darren Shafren |
17-Jan-06 |
Granted: China,Hong Kong |
|
|
Pending: Australia, USA |
||||
|
Divisional Pending: China, Hong Kong
|